Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E, Rahmé R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, Pasquier F, Peterlin P, Chevallier P, Thomas X, Loschi M, Genthon A, Legrand O, Mohty M, Raffoux E, Auberger P, Caulier A, Joris M, Bonmati C, Roth-Guepin G, Lejeune C, Pigneux A, Vey N, Recher C, Ades L, Cluzeau T. Chiche E, et al. Among authors: auberger p. Blood Adv. 2021 Jan 12;5(1):176-184. doi: 10.1182/bloodadvances.2020003159. Blood Adv. 2021. PMID: 33570629 Free PMC article.
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S. Thépot S, et al. Among authors: auberger p. Cell Cycle. 2011 Jul 15;10(14):2323-30. doi: 10.4161/cc.10.14.16399. Epub 2011 Jul 15. Cell Cycle. 2011. PMID: 21654193
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P. Cluzeau T, et al. Among authors: auberger p. Oncotarget. 2012 Apr;3(4):490-501. doi: 10.18632/oncotarget.481. Oncotarget. 2012. PMID: 22577154 Free PMC article.
BCR-ABL/p62/SQSTM1: a cannibal embrace.
Auberger P. Auberger P. Blood. 2012 Oct 25;120(17):3389-90. doi: 10.1182/blood-2012-08-451492. Blood. 2012. PMID: 23100300 Free article.
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D. Willems L, et al. Among authors: auberger p. Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6. Blood. 2013. PMID: 24014241 Free PMC article.
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.
Cluzeau T, Moreilhon C, Mounier N, Karsenti JM, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Auberger P, Fuzibet JG, Cassuto JP, Raynaud S. Cluzeau T, et al. Among authors: auberger p. Blood Cancer J. 2013 Nov 1;3(11):e155. doi: 10.1038/bcj.2013.52. Blood Cancer J. 2013. PMID: 24185502 Free PMC article.
218 results